Lanean...
Cancer immunotherapy with T-cell targeting cytokines: IL-2 and IL-7
Clinical trials have demonstrated that an increased number of effector cells, especially tumor-specific T cells, is positively linked with patients’ prognosis. Although the discovery of checkpoint inhibitors (CPIs) has led to encouraging progress in cancer immunotherapy, the lack of either T cells o...
Gorde:
| Argitaratua izan da: | BMB Rep |
|---|---|
| Egile Nagusiak: | , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Korean Society for Biochemistry and Molecular Biology
2021
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7851446/ https://ncbi.nlm.nih.gov/pubmed/33407991 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5483/BMBRep.2021.54.1.257 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|